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Abstract 1 
Background: Major international guidelines do not offer explicit recommendations on any specific 2 
angiotensin-converting enzyme inhibitor (ACEI) agent over another within the same drug group. 3 
This study compared the effectiveness of lisinopril vs. perindopril in reducing the incidence of 4 
hospital admission due to all-cause, cardiovascular disease and respiratory disease. 5 
 6 
Methods: Adult patients who received new prescriptions of lisinopril or perindopril from 2001 to 7 
2005 in all public hospitals and clinics in Hong Kong were included, and followed up for ≥2 years. 8 
The incidence of admissions due to all-cause, cardiovascular disease and respiratory disease was 9 
evaluated, respectively, by using Cox proportional hazard regression models. The regression models 10 
were constructed with propensity score matching to minimize indication biases. 11 
 12 
Results: A total of 20,252 eligible patients with an average age of 64.5 years (standard deviation 13 
15.0) were included. The admission rate at 24 months within the date of index prescription due to 14 
any cause, cardiovascular disease and respiratory disease among lisinopril vs. perindopril users was 15 
24.8% vs. 24.8%, 13.7% vs. 14.0%  and 6.9% vs. 6.3%, respectively. Lisinopril users were 16 
significantly more likely to be admitted due to respiratory diseases (adjusted hazard ratios 17 
[AHR]=1.25, 95% C.I. 1.08 to 1.43, p=0.002 at 12 months; AHR=1.17, 95% C.I. 1.04 to 1.31, 18 
p=0.009 at 24 months) and all cause (AHR=1.12, 95% C.I. 1.05 to 1.19, p<0.001 at 24 months) than 19 
perindopril users. 20 
 21 
Conclusions: These findings support intra-class differences in the effectiveness of ACEIs, which 22 
could be considered by clinical guidelines when the preferred first-line antihypertensive drugs are 23 
recommended.  (250 words) 24 
 25 
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; PDC, proportion of days covered; 26 
CI, confidence interval; AHR, adjusted hazard ratios 27 
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Introduction 28 
Globally, hypertension is one of the most significant risk factors for cardiovascular disease and all-29 
cause mortality. [1]  The Task Force for the Management of Arterial Hypertension of the European 30 
Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) have 31 
recommended the prescription of angiotensin-converting enzyme inhibitors (ACEIs) for the 32 
treatment of hypertension, heart failure and myocardial infarction. [2]  The ESH/ESC guideline [3], 33 
the National Institute for Health and Care Excellence [4] and 8th Joint National Committee (JNC 34 
8) [5] consistently recommend ACEIs as one of the first line drug classes for management of 35 
arterial hypertension.  In certain situations including diabetic nephropathy, post-myocardial 36 
infarction, heart failure, and left ventricular dysfunction [6, 7], ACEIs are particularly preferred 37 
owing to the ability to provide the greatest end-organ protection. [4]  The enthusiasm to prescribe 38 
ACEIs extends beyond their effectiveness to reduce blood pressure (BP), since as a monotherapy 39 
they are as effective as most other major antihypertensive drug classes. [8] 40 
 41 
Multiple studies have reported comparable antihypertensive efficacy between the multiple ACEIs 42 
and angiotensin II receptor blockers (ARBs) with no consistent differences in clinical outcomes, 43 
including death, cardiovascular events, quality of life, rate of single antihypertensive agent use, 44 
lipid levels, progression to diabetes, left ventricular mass or function, and kidney disease. [9]  In 45 
addition, evidence from the Blood Pressure Lowering Treatment Trialists’ Collaboration showed the 46 
existence of similar BP-dependent effects of ACEIs and ARBs for the risk of cardiovascular and 47 
stroke events; yet the ACEI alone had an added BP-independent benefit in reducing risk of coronary 48 
heart disease. [10]  A more recent meta-analysis documented that ACEIs and ARBs were equally 49 
protective against myocardial infarction and mortality. [11] 50 
 51 
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Nevertheless, there is an important knowledge gap to be addressed.  Evidence from face-to-face 52 
trials that directly compared the effectiveness of different entities of ACEIs were rare, and 53 
meanwhile the major international guidelines [3-5] do not offer explicit recommendations on any 54 
specific ACEI agent over another within the same drug group.  The perindopril and lisinopril are the 55 
two most commonly prescribed ACEIs.  A meta-analysis of randomized controlled trials showed 56 
that perindopril resulted in significantly fewer patients reaching primary end-points, including 57 
stroke, mortality, and myocardial infarction. [12]   When these three endpoints were used as a 58 
composite outcome, the effect size of perindopril alone was larger than that of the combined ACEI 59 
analysis.  Perindopril showed a significant risk reduction of the composite endpoints by 18% when 60 
compared with the overall ACEI effect. [12]  Furthermore, in our recent analysis of a population-61 
based study from 15,622 hypertensive patients, perindopril users were found to have lower all-cause 62 
and cardiovascular mortality than lisinopril users. [13]  63 
 64 
The objective of this study was to compare the effectiveness of perindopril and lisinopril, which 65 
were the two most commonly prescribed ACEIs, on reducing hospital admission due to any cause, 66 
cardiovascular disease and respiratory disease.  We tested the a priori hypothesis that there was no 67 
difference in the incidence of admission between the two drug classes. 68 
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Methods 69 
Data Source 70 
Patient information was extracted from an electronic clinical database, covering the entire Hong 71 
Kong population with more than 7 million people during the study period in the public health care 72 
sector.  Patients’ medication history, sociodemographic characteristics, and clinical diagnoses coded 73 
in the form of International Classification of Diseases (ICD-9) or International Classification of 74 
Primary Care (ICPC-2) in each consultation at different clinic locations were documented by the 75 
clinical management system. This computerized system is the only portal of information entry in all 76 
public health care settings across all geographical regions of Hong Kong (i.e. the New Territories, 77 
Kowloon, and Hong Kong Island).  In all clinical consultations, medical doctors entered the 78 
prescription details as part of their routine practice.  The details were subsequently sent to pharmacy 79 
professionals for drug dispensing.  This electronic patient record system captured all amendments of 80 
prescriptions following the attending physicians’ consultations.  The database has been validated 81 
previously, and we found a high level of completeness of patients’ demographic profiles (100%) and 82 
prescription details (99.8%). [14]  We declared that this database has also been employed for 83 
analysis in previous studies. [13, 15-22]  The present study was performed in accordance with the 84 
ethical guidelines of the Declaration of Helsinki. The study was approved by the Clinical Ethics 85 
Research Committee of the Hospital Authority and the Survey and Behavioral Research Ethics 86 
Committee of The Chinese University of Hong Kong. 87 
 88 
Patients 89 
Patients were eligible if they: (1). visited any public inpatient and outpatient settings in the period 90 
2001-2005; (2). were newly prescribed perindopril or lisinopril as their initial antihypertensive 91 
agent; (3). did not receive antihypertensive drugs other than ACEIs before the index date, which 92 
was defined as the date of the first prescription record.  We excluded subjects whose ACEI 93 
prescriptions lasted for less than 1 month; and whose antihypertensive agent was switched to 94 
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another medication for 2 years within the index date.  Concomitant comorbidities of all patients 95 
were represented by the corresponding ICD-9 or ICPC-2 codes documented in the computer, and all 96 
patients were followed-up for 2 years.  97 
 98 
Outcomes Variables and Covariates  99 
The primary outcome measures consisted of the incidence of hospital admission due to any cause, 100 
cardiovascular disease, and respiratory disease, respectively, based on physician diagnoses.  The 101 
incidence of admission due to cardiovascular diseases was identified with respect to coronary heart 102 
disease or stroke (ICD-9: coronary heart diseases: 410–414, heart failure: 428, cerebrovascular 103 
disease: 430–435, 437, 438; ICPC-2: cardiovascular or cerebrovascular disease: K74-K77, K84, 104 
K90, K91, K99). The respiratory diseases captured in the system included chronic obstructive 105 
airway disease, asthma, pneumoconiosis and other lung diseases that are major complications of 106 
pulmonary hypertension or complications that are commonly seen among patients on ACEIs (ICD-9: 107 
491–493, 495, 496, 500–508, 510–513, 516, 517.1, 517.2, 517.8, 518.1, 518.2, 518.3, 518.5, 518.81, 108 
518.82, 518.89, 519.1, 519.4, 519.8; ICPC-2: R79, R95, R96).  The proportions of new-onset 109 
cardiovascular and respiratory diseases were captured from the hospitalization information system 110 
of the Hospital Authority. 111 
 112 
The variable tested for association with the outcomes was the medication prescribed (lisinopril vs. 113 
perindopril).  We controlled for age, sex, socioeconomic status (SES), service types (inpatient vs. 114 
specialist outpatient vs. general outpatient), the Proportion of Days Covered (PDC) as a measure of 115 
medication adherence, and the number of comorbidities.  As a proxy measure of SES, we classified 116 
patients into recipients and non-recipients of social security allowance.  We categorized 117 
comorbidities into “cardiovascular diseases”, “respiratory diseases”, “renal diseases” and “diabetes 118 
or impaired glucose tolerance”, based on the respective ICD-9 and ICPC-2 codes. [22]  The 119 
interval-based PDC has been recognized as an internationally accepted metric to evaluate 120 
Page 7 of 17 
medication adherence in database research. [23-25]  The PDC was derived from dividing the time 121 
period with prescriptions by the total period of follow-up.  For patients who died within 2 years 122 
after the index prescription, the PDC was estimated by adopting the time period between the index 123 
date and the death date.  The medication adherence was regarded as high (PDC ≥0.80) or low (PDC 124 
<0.80) according to international standard. [25-27] 125 
 126 
Statistical Analysis 127 
The demographic and clinical characteristics of patients prescribed lisinopril vs. perindopril were 128 
compared by Pearson’s Chi-square tests for categorical variables and Student’s t-tests for 129 
continuous variables.  We tabulated the incidence of hospital admissions due to any cause, 130 
cardiovascular disease and respiratory disease, respectively, across different independent variables.  131 
The Kaplan-Meier method with the log-rank test was adopted to compare the difference between 132 
lisinopril users vs. perindopril users in their incidence of cause-specific hospital admission.  A Cox 133 
proportional hazard regression analysis [28] was modelled to compare the mortality rates of the two 134 
drug groups, adjusting for age, sex, SES, service types, the PDC, and the number of comorbidities. 135 
Three models were constructed for admissions due to any cause, cardiovascular disease and 136 
respiratory diseases, respectively, where hazard ratios and the corresponding 95% confidence 137 
intervals (95% CI) were evaluated.  The medication dosages were controlled in additional 138 
regression analyses to detect for differences in hazard ratios. 139 
 140 
To minimize the influence of treatment indication bias caused by different baseline characteristics 141 
of the two drug groups, we performed propensity score matching which was incorporated into the 142 
Cox proportional hazard models.  The score was estimated by a logistic regression model with 143 
ACEIs prescribed against age, sex, service types, and SES.  The probability of prescribing lisinopril 144 
compared with perindopril was predicted according to the baseline characteristics of each patient.  A 145 
propensity score was assigned for each patient.  The Cox proportional hazard analyses adjusted for 146 
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the propensity scores and other confounding factors. This standardized methodology to minimize 147 
indication bias has been utilized by other studies. [29-31]  All tests of significance were two-tailed, 148 
where p values less than 0.05 were regarded as statistically significant.  We performed all statistical 149 
analyses with the Statistical Package for Social Sciences (version 16.0, Chicago, IL). 150 
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Results 151 
Participant characteristics 152 
The baseline characteristics of all patients were presented in Table 1.  Their average age was 64.5 153 
years (SD 15.0), and 49.2% were female subjects.  There was no significant difference in age and 154 
gender between users of perindopril and lisinopril.  Slightly more patients who received lisinopril 155 
were recipients of public financial assistance (17.4% vs. 14.8%, p<0.001).  Higher proportion of 156 
lisinopril users attended specialist out-patient clinics (37.3% vs. 32.0%, p<0.001) when compared 157 
with perindopril users.  Patients prescribed lisinopril had higher medications adherence at 6 months 158 
(PDC ≥ 0.80: 34.8% vs. 30.2%), 1 year (48.9% vs. 41.7%) and 2 years (36.0% vs. 28.8%, all 159 
p<0.001).  Lisinopril users were prescribed higher dosages (>5 mg/day: 14.8% vs. 7.2%, p<0.001) 160 
(Table 1). 161 
 162 
Profile of admissions due to any cause, cardiovascular disease and respiratory disease 163 
Table 2 shows the participant characteristics according to cause-specific hospital admissions.  164 
Among patients who were still survived, the proportion of subjects admitted to hospitals 6 months 165 
within the date of index prescription due to any cause, cardiovascular disease and respiratory 166 
disease was 12.2%, 7.6% and 3.1%, respectively.   Patients admitted due to any cause (age ≥70 167 
years; 58.5% vs. 36%), cardiovascular disease (65.9% vs. 36.5%), and respiratory disease (77.6% 168 
vs. 37.5%) were older than those not admitted.  For all types of admissions, there was a higher 169 
proportion of male patients and recipients of public financial assistance (Table 2).  When compared 170 
with patients who were not admitted, those admitted due to any cause (57.5% vs. 56.6%) and 171 
respiratory disease (58.5% vs. 56.7%) had higher proportions taking lisinopril, as well as having 172 
PDC ≥0.80.  At 12 months, the proportion of patients admitted due to any cause, cardiovascular and 173 
respiratory disease was 20.4%, 11.3% and 4.9%.  The corresponding figures at 24 months were 174 
31.1%, 16.1% and 7.1% (Table 3).  Among admissions due to any cause and respiratory diseases, 175 
the majority were lisinopril users.  The admission rate at 24 months within the date of index 176 
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prescription due to any cause, cardiovascular disease and respiratory disease among lisinopril vs. 177 
perindopril users was 24.8% vs. 24.8%, 13.7% vs. 14.0%  and 6.9% vs. 6.3%, respectively. 178 
 179 
Comparison between lisinopril and perindopril 180 
Unadjusted and adjusted Cox proportional hazard regression analyses with propensity score 181 
matching were performed to compare the disease-specific admission rates between lisinopril and 182 
perindopril (Table 4).  From regression analysis, lisinopril users were significantly more likely to be 183 
admitted due to respiratory diseases (adjusted hazard ratios [AHR]=1.25, 95% C.I. 1.08 to 1.43, 184 
p=0.002 at 12 months; AHR=1.17, 95% C.I. 1.04 to 1.31, p=0.009 at 24 months) and any cause 185 
(AHR=1.12, 95% C.I. 1.05 to 1.19, p<0.001 at 24 months) than perindopril users. 186 
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Discussion 187 
Statement of Major Findings 188 
The present study included more than 20,000 patients newly prescribed ACEIs and compared the 189 
incidence of hospital admission between patients who received lisinopril and perindopril, where 190 
indication bias was controlled by propensity score matching.   It was found that the odds of hospital 191 
admission was significantly higher among lisinopril users when compared with perindopril users at 192 
24 months due to any cause (by 12%) and respiratory diseases (by 17%).  These findings supported 193 
an intra-class difference in the pharmacological benefits within the ACEI drug group. 194 
 195 
Relationship with Literature and Explanation of Findings 196 
ACEIs are the only drug class recommended for all of the compelling indications listed in the JNC 197 
7 guideline.  Lisinopril and perindopril are commonly prescribed.  They belong to the carboxyl-198 
containing ACEIs with identical duration of action (24 hours), and both were eliminated via the 199 
kidneys. [32]  Lisinopril has a longer serum half-life (11-12 hours) than perindopril (3-10 hours).  200 
There have been very few studies which directly compared the effectiveness of lisinopril and 201 
perindopril on reducing the incidence of cardiovascular and respiratory disease-related admissions.  202 
A meta-analysis of randomized controlled trials of ACEI therapy for any cardiovascular 203 
outcomes [12] showed that the effect size of perindopril was higher than that of the combined ACEI 204 
class.  The risk reduction of composite cardiovascular endpoints was 18% for perindopril users but 205 
was lowered to 5% only if perindopril was excluded from the analysis.  The authors concluded that 206 
the survival benefits differed according to different ACEIs prescribed.  This statement was 207 
corroborated by another study conducted by Comini and colleagues, who compared the 208 
effectiveness of five ACEIs (enalapril, perindopril, quinapril, ramipril, and trandolapril) at 209 
equihypotensive doses on increasing endothelial nitric oxide synthase protein expression and 210 
activity in the aorta and cardiac myocytes. [33]  A highly significant effect was observed with 211 
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perindopril when compared with other ACEIs, which provided further evidence in favor of the 212 
differential effects of ACEI therapy.  Hence, the clinical benefits associated with these medications 213 
might not solely reflect a class effect extending their benefit beyond BP-lowering effect.  In 214 
addition, Pilote and colleagues performed two retrospective studies using linked hospital discharge 215 
and prescription databases in Canada.  They found that patients older than 65 years who suffered 216 
from an acute myocardial infarction were significantly less likely to die if they were prescribed 217 
ramipril compared with those on other ACEIs (enalapril, fosinopril, captopril, quinapril, and 218 
lisinopril). [34]  They also showed that elderly patients who had heart failure had higher mortality 219 
rate 30 days after hospital discharge among those prescribed captopril or enalapril compared with 220 
Ramipril. [35]  Together with our previous studies which showed that hypertensive patients who 221 
received lisinopril were more likely than perindopril users to die from cardiovascular disorders or 222 
be admitted due to renal disease or diabetes, [13, 36] the conclusion of this study was compatible 223 
with those from existing literature.  The difference in their effectiveness to reduce respiratory 224 
disease and all-cause admissions might be due to their different pharmacokinetic and 225 
pharmacodynamics activities.  Also, this study reported that patients prescribed perindopril had 226 
lower medication adherence levels than lisinopril users.  The exact mechanism where they confer 227 
different effects is yet to be explored.  Our study is unique as it included patients with ethnicities 228 
that have not been previously studied. It is known that the pharmacological responses to different 229 
antihypertensive drugs differ according to different ethnicities [37] – hence our findings allow the 230 
conclusions of previous studies to be more generalizable. 231 
 232 
Strengths and Limitations  233 
This is the first study of this scale which included a large number of patients newly prescribed two 234 
commonly used ACEIs in the whole territory of Hong Kong, using a validated and comprehensive 235 
database. [14]  The standardized prescription and dispensing practices which were under regular 236 
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audit in the public healthcare system enhanced the robustness of the present analysis.  The use of 237 
ICD-9 and ICPC-2 as internationally recognized strategies for disease coding, and the ability of the 238 
electronic pharmacy system to include medication details in all clinic visits at different geographical 239 
regions provide an accurate source of data.  However, some limitations should be addressed here.  240 
Firstly, the inherent assumption of database analysis where patients were actually taking the 241 
prescribed medications needs to be taken into account.  Hence we have also incorporated PDC as a 242 
universally accepted metric into the Cox regression models. [23-25]  Also, the follow-up period of 243 
this study was up to two years – and it is unknown whether the observed differences in hospital 244 
admission between the two groups could be sustained in the long term.  Thirdly, there exist 245 
heterogeneity in the baseline characteristics of patients between the two drug groups, and critics 246 
might argue that indication bias could influence the results against the null hypothesis.  Therefore 247 
we have attempted to address this concern employing propensity score matching, which has been 248 
widely used internationally for analyzing administrative databases. [30, 36]  It should also be noted 249 
that the two medications have exactly the same compelling indications and contraindications, and 250 
both were available in all the public clinics where the choice of prescription was up to the 251 
physicians-in-charge.  Finally, due to the non-randomized nature of assigning subjects into the two 252 
groups, some residual confounders that were not captured by the database might introduce bias, 253 
including previous comorbidities, prior experience of hospital admission, lifestyle habits after 254 
clinical consultations, and concomitant medications taken by the patients. 255 
 256 
Conclusions 257 
This study reported intra-class difference of ACEIs with respect to their effectiveness to reduce all-258 
cause and respiratory disease admissions, among hypertensive patients who received their first-ever 259 
antihypertensive medications. The better outcomes seen in perindopril vs. lisinopril provide an 260 
important clinical implication to both researchers and physicians.  Lisinopril alone may not be 261 
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adequate to represent the entire ACEI class in interpretation of existing trials, which almost 262 
exclusively used lisinopril as “representative of ACEIs”. Future studies should be performed to 263 
compare the effectiveness of different drugs within the ACEI class on patient-oriented outcomes by 264 
rigorously designed trials, preferably in patients of different races.  The hypothesis where one ACEI 265 
is superior to another should be further tested prospectively, as it also exerts an impact on the 266 
formulation of future clinical guidelines on recommendation of antihypertensive treatments. 267 
 268 
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Table 1 Characteristics of study participants (N=20,252) 
 
 
 Overall 
(n=20,252) 
Perindopril users 
(n=8,731) 
Lisinopril users 
(n=11,521) 
p 
Age 
<49 
49-59 
60-69 
≥ 70 
 
3,523 (17.4%) 
3,986 (19.7%) 
4,340 (21.4%) 
8,403 (41.5%) 
 
1,460 (16.7%) 
1,729 (19.8%) 
1,881 (21.5%) 
3,661 (41.9%) 
 
2,063 (17.9%) 
2,257 (19.6%) 
2,459 (21.3%) 
4,742 (41.2%) 
 
0.177 
Sex  
Male 
Female 
 
10,292 (50.8%) 
9,960 (49.2%) 
 
4,430 (50.7%) 
4,301 (49.3%) 
 
5,862 (50.9%) 
5,659 (49.1%) 
 
0.841 
Public financial assistance 
Non-recipients  
Recipients 
 
16,952 (83.7%) 
3,300 (16.3%) 
 
7,436 (85.2%) 
1,295 (14.8%) 
 
9,516 (82.6%) 
2,005 (17.4%) 
 
<0.001 
Service type 
In-patient 
Specialist outpatient 
Accident & Emergency 
General outpatient 
Others 
 
6,553 (32.4%) 
7,091 (35.0%) 
128 (0.6%) 
5,739 (28.3%) 
741 (3.7%) 
 
2,907 (33.3%) 
2,798 (32.0%) 
63 (0.7%) 
2,731 (31.3%) 
232 (2.7%) 
 
3,646 (31.6%) 
4,293 (37.3%) 
65 (0.6%) 
3,008 (26.1%) 
509 (4.4%) 
 
<0.001 
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Drug adherence (PDC at 6 months) 
<0.80 
≥ 0.80 
 
13,610 (67.2%) 
6,642 (32.8%) 
 
6,097 (69.8%) 
2,634 (30.2%) 
 
7,513 (65.2%) 
4,008 (34.8%) 
 
<0.001 
Drug adherence (PDC at 1 year) 
<0.80 
≥ 0.80 
 
10,970 (54.2%) 
9,282 (45.8%) 
 
5,086 (58.3%) 
3,645 (41.7%) 
 
5,884 (51.1%) 
5,637 (48.9%) 
 
<0.001 
Drug adherence (PDC at 2 years) 
<0.80 
≥ 0.80 
 
13,591 (67.1%) 
6,661 (32.9%) 
 
6,214 (71.2%) 
2,517 (28.8%) 
 
7,377 (64.0%) 
4,144 (36.0%) 
 
<0.001 
Drug dosage (mg/day) 
0-2.5 
>2.5-5.0 
>5.0-7.5 
>7.5-10 
>10 
 
12,389 (61.2%) 
5,526 (27.3%) 
240 (1.2%) 
1,069 (5.3%) 
1,028 (5.1%) 
 
5,798 (66.4%) 
2,300 (26.3%) 
148 (1.7%) 
151 (1.7%) 
334 (3.8%) 
 
6,591 (57.2%) 
3,226 (28.0%) 
92 (0.8%) 
918 (8.0%) 
694 (6.0%) 
 
<0.001 
 
PDC: Proportion days covered with the lisinopril and perindopril.  The percentages are across rows.  The p values represent the comparison between 
the perindopril and lisinopril groups using Pearson chi-square tests.
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Table 2 Profiles of patient admission at 6 months 
  All-cause Cardiovascular disease Respiratory disease 
  Not Admitted Admitted Not Admitted Admitted Not Admitted Admitted 
Mean Age (S.D.) 63.3 66.2 63.3 67.6 63.5 68.8 
Age n=16664 n=2323 n=17539 n=1448 n=18393 n=594 
≤ 49 3,249 (19.5%) 239 (10.3%) 3,417 (19.5%) 71 (4.9%) 3,472 (18.9%) 16 (2.7%) 
50-59 3,636 (21.8%) 297 (12.8%) 3,774 (21.5%) 159 (11%) 3,905 (21.2%) 28 (4.7%) 
60-69 3,779 (22.7%) 428 (18.4%) 3,943 (22.5%) 264 (18.2%) 4,118 (22.4%) 89 (15%) 
≥ 70 6,000 (36%) 1,359 (58.5%) 6,405 (36.5%) 954 (65.9%) 6,898 (37.5%) 461 (77.6%) 
Sex              
Male 8346 (50.1%) 1244 (53.6%) 8796 (50.2%) 794 (54.8%) 9259 (50.3%) 331 (55.7%) 
Female 8318 (49.9%) 1079 (46.4%) 8743 (49.8%) 654 (45.2%) 9134 (49.7%) 263 (44.3%) 
Public financial assistance             
Non-recipients  14355 (86.1%) 1667 (71.8%) 15010 (85.6%) 1012 (69.9%) 15652 (85.1%) 370 (62.3%) 
Recipients 2309 (13.9%) 656 (28.2%) 2529 (14.4%) 436 (30.1%) 2741 (14.9%) 224 (37.7%) 
Service type             
In-patient 3779 (22.7%) 1652 (71.1%) 4234 (24.1%) 1197 (82.7%) 4934 (26.8%) 497 (83.7%) 
Specialist outpatient 6493 (39%) 506 (21.8%) 6812 (38.8%) 187 (12.9%) 6932 (37.7%) 67 (11.3%) 
Accident & Emergency 113 (0.7%) 10 (0.4%) 120 (0.7%) 3 (0.2%) 121 (0.7%) 2 (0.3%) 
General outpatient 5589 (33.5%) 122 (5.3%) 5670 (32.3%) 41 (2.8%) 5689 (30.9%) 22 (3.7%) 
Others (e.g. day hospital, community 690 (4.1%) 33 (1.4%) 703 (4%) 20 (1.4%) 717 (3.9%) 6 (1%) 
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program) 
ACE Inhibitor             
Perindopril 7225 (43.4%) 987 (42.5%) 7541 (43%) 671 (46.3%) 7967 (43.3%) 245 (41.2%) 
Lisinopril 9439 (56.6%) 1336 (57.5%) 9998 (57%) 777 (53.7%) 10426 (56.7%) 349 (58.8%) 
Drug adherence (PDC at 6 months)             
<0.80 11229 (67.4%) 1238 (53.3%) 11702 (66.7%) 765 (52.8%) 12151 (66.1%) 316 (53.2%) 
≥ 0.80 5435 (32.6%) 1085 (46.7%) 5837 (33.3%) 683 (47.2%) 6242 (33.9%) 278 (46.8%) 
 
PDC: Proportion of Days Covered as a measure of medication adherence
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Table 3 Incidence of hospital admission at 12 months and 24 months according antihypertensive agents and medication 
adherence 
 
All-cause 
Cardiovascular disease Respiratory disease 
  Not Admitted Admitted Not Admitted Admitted Not Admitted Admitted 
12 months       
Medication 15764 3223 17054 1933 18106 881 
Perindopril 6870 (43.6%) 1342 (41.6%) 7345 (43.1%) 867 (44.9%) 7864 (43.4%) 348 (39.5%) 
Lisinopril 8894 (56.4%) 1881 (58.4%) 9709 (56.9%) 1066 (55.1%) 10242 (56.6%) 533 (60.5%) 
Drug adherence (PDC) at 12 months          
<0.80 8094 (51.3%) 1620 (50.3%) 8741 (51.3%) 973 (50.3%) 9241 (51%) 473 (53.7%) 
≥ 0.80 7670 (48.7%) 1603 (49.7%) 8313 (48.7%) 960 (49.7%) 8865 (49%) 408 (46.3%) 
24 months   
    
 Medication 14488 4499 16358 2629 17730 1257 
Perindopril 6384 (44.1%) 1828 (40.6%) 7064 (43.2%) 1148 (43.7%) 7697 (43.4%) 515 (41%) 
Lisinopril 8104 (55.9%) 2671 (59.4%) 9294 (56.8%) 1481 (56.3%) 10033 (56.6%) 742 (59%) 
Drug adherence (PDC) at 24 months          
<0.80 9352 (64.5%) 2974 (66.1%) 10567 (64.6%) 1759 (66.9%) 11443 (64.5%) 883 (70.2%) 
≥ 0.80 5136 (35.5%) 1525 (33.9%) 5791 (35.4%) 870 (33.1%) 6287 (35.5%) 374 (29.8%) 
 
PDC: Proportion Days Covered as a measure of medication adherence
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Table 4 Hospital admissions due to any cause, cardiovascular disease and respiratory disease at 6 months, 12 months 
and 24 months after the index prescription date with propensity score matching 
 
  Cardiovascular disease Respiratory disease All cause 
  
  
Crude HR 
(95% C.I.) 
P  Adjusted HR 
(95% C.I.) 
P  Crude HR 
(95% C.I.) 
P Adjusted HR 
(95% C.I.) 
P  Crude HR 
(95% C.I.) 
P  Adjusted HR 
(95% C.I.) 
P 
  
12-
months 
  
   
  
   
  
  
  
Perindopril 1.000 (referent)  
 
1.000 (referent)  
 
1.000 (referent)  
 
1.000 (referent)  
 
1.000 (referent)  
 
1.000 (referent)    
Lisinopril 0.926  
(0.847, 1.013) 
0.092 0.925  
(0.845, 1.013) 
0.091 1.169  
(1.021, 1.338) 
0.024 1.245  
(1.084, 1.429) 
0.002 1.064  
(0.992, 1.141) 
0.083 1.058  
(0.986, 1.135) 
0.120 
24-
months 
  
   
  
   
  
  
  
Perindopril 1.000 (referent)  
 
1.000 (referent)  
 
1.000 (referent)  
 
1.000 (referent)  
 
1.000 (referent)  
 
1.000 (referent)    
Lisinopril 0.973  
(0.901, 1.051) 
0.493 0.977  
(0.904, 1.056) 
0.56 1.101  
(0.984, 1.232) 
0.092 1.166 
(1.040, 1.307) 
0.009 1.118 
(1.054, 1.187) 
<0.001 1.116  
(1.051, 1.185) 
<0.001 
 
Crude HR, Crude Hazard Ratios; Adjusted HR, Adjusted Hazard Ratios 
* The propensity scores were matched for age, sex, public financial assistance, service type, initial dosage, and Proportion Days Covered (PDC). 
